• 4-year exclusive global distribution agreement with EZZ Life Sciences
• Minimum sales target of $10m over the 4-year term
• Expands Aumake's high-margin nutraceutical product range

Aumake Limited has announced a strategic partnership with EZZ Life Sciences (ASX:EZZ) via a 4-year exclusive global distribution agreement targeting minimum sales of $10m. Aumake has a well-proven track record in the sales of high-margin nutraceutical products, with more than $2.1m in sales recorded since 2025 across wholesale B2B and B2C channels. The agreement signed today builds on this established sales channel through exclusive rights to a range of high-value products from EZZ Life Sciences, including EZZ Glutathione Health Support, EZZ Vitality Boost, and EZZ Sleep, with scope to expand to further products. The agreement sets out minimum sales targets of $2.5m per year each year for four years, totaling $10 million Australian dollars for the product range. The collaboration and distribution agreement includes a cooperative manufacturing model which ensures healthy margins, with sales and marketing driven through Aumake's proven B2C e-commerce platforms and B2B distribution network. The nutraceutical products segment is the highest margin segment within Aumake's Nutritionals products channel, and this agreement will drive high-margin sales in this segment. The distribution agreement is a global exclusive agreement for the products that are included and for the new products that will be co-developed to meet the demand in the China market.

The agreement sets out minimum sales targets of $2.5m per year each year for four years, totaling $10 million Australian dollars for the product range.

Aumake is at a pivotal and exciting moment, and the company looks forward to accelerating its growth and adding innovative strategies that deliver additional value to both the brands it distributes and its consumers in China, which will be announced in the coming weeks.